Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor B-cell infiltration in platinum-treated advanced muscle-invasive urothelial carcinoma.

Molecular oncology·2026
Same author

Real-World Data on the Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced/Metastatic Breast Cancer.

World journal of oncology·2026
Same author

Role of Local Treatment to the Prostate in Patients With de Novo Low-volume Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Receptor Pathway Inhibitors.

European urology open science·2026
Same author

Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study.

Journal for immunotherapy of cancer·2026
Same author

CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.

The New England journal of medicine·2026

Related Experiment Video

Updated: Apr 21, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

19.4K

Precision medicine for prostate cancer.

Myria Galazi1, Alejo Rodriguez-Vida, Tony Ng

  • 1Department of Medical Oncology, Guy's Hospital, London, SE1 9RT, UK.

Expert Review of Anticancer Therapy
|October 31, 2014
PubMed
Summary

Metastatic castration-resistant prostate cancer treatment is improving with genomic insights. Understanding key genetic changes like androgen receptor signaling can guide future personalized therapies for this lethal disease.

Keywords:
ETS fusion gene rearrangementsPI3K/AKT/mTOR pathwayPTEN lossandrogen receptorcastration-resistant prostate cancerprecision medicine

More Related Videos

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

1.5K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.1K

Related Experiment Videos

Last Updated: Apr 21, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

19.4K
Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

1.5K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.1K

Area of Science:

  • Oncology
  • Genomics
  • Molecular Biology

Background:

  • Metastatic castration-resistant prostate cancer (mCRPC) is a significant cause of cancer mortality.
  • Despite advances, mCRPC treatment often relies on empirical approaches.
  • Genomic sequencing has enhanced prostate cancer molecular classification.

Purpose of the Study:

  • To review key genomic aberrations in prostate cancer.
  • To discuss the potential of genomic data in guiding mCRPC therapy.
  • To highlight the evolving role of genomic information in clinical trials.

Main Methods:

  • Literature review and discussion of genomic alterations.
  • Focus on androgen receptor signaling, ETS gene rearrangements, and PTEN loss.
  • Examination of the integration of genomic data in early-phase clinical trials.

Main Results:

  • Genomic sequencing reveals critical aberrations in prostate cancer.
  • Androgen receptor signaling, ETS rearrangements, and PTEN loss are frequently observed.
  • Translating genomic findings into predictive biomarkers is still developing.

Conclusions:

  • Genomic data offers a pathway to personalized prostate cancer care.
  • Further integration of genomic insights into clinical trials is crucial.
  • Personalized therapeutic strategies hold promise for improving outcomes in mCRPC.